Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Purpose: Neoadjuvant PD-1 blockade is a promising treatment for resectable non–small cell lung cancer (NSCLC), yet immunologic mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samples from a phase II clinical trial (NCT02259621), we explored whether the peripheral T-cell clonotypic dynamics can serve as a biomarker for response to neoadjuvant PD-1 blockade. Experimental Design: T-cell receptor (TCR) sequencing was performed on serial peripheral blood, tumor, and normal lung samples from resectable NSCLC patients treated with neoadjuvant PD-1 blockade. We explored the temporal dynamics of the T-cell repertoire in the peripheral and tumoral compartments in response to neoadjuvant PD-1 blockade by using the TCR as a molecular barcode. Results: Higher intratumoral TCR clonality was associated with reduced percent residual tumor at the time of surgery, and the TCR repertoire of tumors with major pathologic response (MPR; <10% residual tumor after neoadjuvant therapy) had a higher clonality and greater sharing of tumor-infiltrating clonotypes with the peripheral blood relative to tumors without MPR. Additionally, the posttreatment tumor bed of patients with MPR was enriched with T-cell clones that had peripherally expanded between weeks 2 and 4 after anti–PD-1 initiation and the intratumoral space occupied by these clonotypes was inversely correlated with percent residual tumor. Conclusions: Our study suggests that exchange of T-cell clones between tumor and blood represents a key correlate of pathologic response to neoadjuvant immunotherapy and shows that the periphery may be a previously underappreciated originating compartment for effective antitumor immunity. See related commentary by Henick, p. 1205
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“In addition to PD-L1 expression (8), other immune correlates of clinical response to PD-1 blockade include CD8þ T-cell infiltration (9), the presence of PD-1þCD8þ T cells at the invasive tumor margin (9, 10), high densities of CD45ROþgranzymeþ T cells (11), IFNg-associated gene expression (12), the proximity of PD1þ t…”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“Blockade of PD-1 signaling with anti–PD-1/PD-L1 antibodies reinvigorates preexisting tumor-specific T-cell clones (7).”
BackgroundSelf-citationTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Self-citationNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · cited 7×
“We recently detected peripheral expansion of neoantigenspecific peripheral T-cell clonotypes that were also observed in high abundance in the posttreatment tumor in a single patient with MPR (3).”
BackgroundMethodInfluentialSelf-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · cited 1×
“Although anti–PD-1 has been reported to reinvigorate peripheral T-cell clones that are also present in the tumor (24), our study further suggests that anti–PD-1 may induce an exchange of reinvigorated effector PD1þ T cells between the periphery and tumor, where they may contribute to tumor regression.”
BackgroundClonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534 · cited 1×
“Furthermore, the level of clonal sharing of ITCs with blood and normal lung was significantly higher in MPR patients relative to non-MPR patients, whereas non-MPRs had more tumor-resident–only ITCs, consistent with the notion that intrinsic tumor-resident T-cell repertoire may likely to be exhausted with low tumor rea…”
ResultComprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988 · cited 1×
“In addition to PD-L1 expression (8), other immune correlates of clinical response to PD-1 blockade include CD8þ T-cell infiltration (9), the presence of PD-1þCD8þ T cells at the invasive tumor margin (9, 10), high densities of CD45ROþgranzymeþ T cells (11), IFNg-associated gene expression (12), the proximity of PD1þ t…”
BackgroundKamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854 · cited 1×
“Peripheral expansion of intratumoral clonotypes (14) and proliferation of peripheral Ki-67þ PD-1þCD8þT cells (15) have been linked with clinical benefit from PD-1 blockade in advanced NSCLC using pretreatment tumor specimens, but connecting these changes with the intratumoral immune response after treatment has not be…”
Background
Cited by
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citationDynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Self-citationSholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 283
Metadata
- Authors
- Zhang, J., Ji, Z., Caushi, J. X., El Asmar, M., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., Chaft, J. E., Reuss, J. E., Tam, A. J., Blosser, R. L., Abu-Akeel, M., Sidhom, J.-W., Zhao, N., Ha, J. S., Jones, D. R., Marrone, K. A., Naidoo, J., Gabrielson, E., Taube, J. M., Velculescu, V. E., Brahmer, J. R., Housseau, F., Hellmann, M. D., Forde, P. M., Pardoll, D. M., Ji, H., & Smith, K. N.
- Venue
- Clinical Cancer Research
- Published
- 2020-03-13
- Volume
- 26
- Issue
- 6
- Pages
- 1327-1337
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2991240940
- Cited by
- 152
- References
- 13
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2931
- The paper
- Zhang, J., Ji, Z., Caushi, J. X., El Asmar, M., Anagnostou, V., Cottrell, T. R., Chan, H. Y., Suri, P., Guo, H., Merghoub, T., Chaft, J. E., Reuss, J. E., Tam, A. J., Blosser, R. L., Abu-Akeel, M., Sidhom, J.-W., Zhao, N., Ha, J. S., Jones, D. R., . . . Smith, K. N. (2020). Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.